truBrain, creator of the world’s first nootropic drink, was featured in this week’s Power Pitch segment of CNBC’s Power Lunch to discuss the company’s traction and growth strategy, as well as their recent equity offering through the crowdfunding platform CircleUp.
The segment highlights truBrain’s success in developing novel products that are validated by neurotechnology, while also discussing its decision to join CircleUp to raise $500,000 to jumpstart massive user acquisition and invest in new product development.
During his interview on the show, CEO of truBrain, Chris Thompson stated, “Our mission is to quantify attention and productivity in the brain, and optimize performance.”
Also mentioning that the company’s scientists have conducted two pilot studies and used wearables to measure the products impact on the brain waves, Thompson noted, “We observed that truBrain versus placebo showed a higher amplitude of alpha brain waves in the parietal and temporal lobes. Incrased alpha brainwaves may be associated with better engaged attention.”
In regards to any consumer doubts, Thompson added, “I do think even if you look at certain things there’s always a bell curve of response. There will be a slice that it doesn’t actually work for them or it doesn’t do anything noticeable. But, for the mass majority, there’ll be something. We don’t want to make these bold, outrageous claims.”
The company’s flagship product, think drinks, was designed by neuroscientists to provide direct support for focus instead of caffeine-induced alertness. When people have less than ideal sleep and a lot of work to do, they usually opt for energy drinks and coffee.
These options help people stay alert, but from truBrain’s research, they have found that it’s not being alert that helps people be more productive and efficient–it’s clear, balanced focus. This has led the company to gaining a loyal following with stellar member satisfaction and support. They have consistently posted a 25% growth in member base month over month throughout the company’s lifespan and they are already shipping to over 50 countries worldwide.
The company is now making inroads to new growth opportunities such as corporate office buying programs, B2B partnerships, and retail distribution. Lead neuroscientists, PhDs Dr. Andrew Hill and Dr. Aida Attar, develop and bring to market nutrient-based products that support peak performance of healthy individuals. These products lie in the space in between food and pharma–functional beverages with active nootropics.
Nootropics are a rare and impressive category of ingredients that show huge potential in cognitive enhancement. This company is leveraging real science, has a product-market fit, and is just in need of seed capital to explode.
Have a crowdfunding offering you'd like to share? Submit an offering for consideration using our Submit a Tip form and we may share it on our site!